These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 4318813

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. [Preparation and testing of an anti-aphthous vaccine with A22 virus cultured in tissue cultures].
    Orlov SD, Bykov IA, Ratner LS, Moutouzkina ZP, Ignatieva VS.
    Bull Off Int Epizoot; 1969; 71(3-4):393-5. PubMed ID: 4323527
    [No Abstract] [Full Text] [Related]

  • 23. Studies on the immune response of foot-and-mouth disease vaccine type Asia-1 in pregnant ewes, lambs and evaluation of type O vaccine by challenge.
    Nair SP, Sen AK.
    Acta Virol; 1994 Oct; 38(5):257-61. PubMed ID: 7725999
    [Abstract] [Full Text] [Related]

  • 24. Development of an effective vaccine against foot-and-mouth disease with partially purified and concentrated virus antigen.
    Sen AK, Saha SN.
    Acta Virol; 1994 Feb; 38(1):17-9. PubMed ID: 8067308
    [Abstract] [Full Text] [Related]

  • 25. [Testing the activity of anti-foot-and-mouth disease aluminum hydroxide formol vaccine on guinea pigs].
    Kuleshova LA, Kozlovskiĭ GA, Sorvachev EV, Murashkin VI.
    Veterinariia; 1969 May; 5():25-7. PubMed ID: 5381315
    [No Abstract] [Full Text] [Related]

  • 26. [Measurement of immunity of cattle against foot-and-mouth disease with the use of the sheep test].
    Fédida M, Dannacher G, Thomas JP, Peillon M, Coudert M.
    Bull Off Int Epizoot; 1970 May; 73(7):687-701. PubMed ID: 4323107
    [No Abstract] [Full Text] [Related]

  • 27. [On the production of monovalent foot-and-mouth disease vaccine concentrate from tissue culture virus type O].
    Mitev G, Wassilewa L, Tekerlekov P.
    Arch Exp Veterinarmed; 1966 Mar; 20(1):85-90. PubMed ID: 4293436
    [No Abstract] [Full Text] [Related]

  • 28. [Post-vaccinal immunity against heterologous subtypes of the foot-and-mouth disease virus].
    Sobko AI, Sokolov LN, Mishchenko VA, Maslova NS, Dudnikov AI.
    Veterinariia; 1977 Sep; (9):42-4. PubMed ID: 202059
    [No Abstract] [Full Text] [Related]

  • 29. Derivatives of aziridine as inactivants for foot-and-mouth disease virus vaccines.
    Warrington RE, Cunliffe HR, Bachrach HL.
    Am J Vet Res; 1973 Aug; 34(8):1087-91. PubMed ID: 4356910
    [No Abstract] [Full Text] [Related]

  • 30. Some problems of testing foot-and-mouth disease vaccines. II. Potency testing.
    Soós T.
    Acta Vet Hung; 1987 Aug; 35(3):331-42. PubMed ID: 2829602
    [No Abstract] [Full Text] [Related]

  • 31. Basis of the preparation of A22 type foot-and-mouth disease vaccine in Turkey.
    Okay G, Sutcu M, Bayramoglu O, Oral M, Unluleblebici N, Senturk M, Girard HC.
    Bull Off Int Epizoot; 1969 Aug; 71(3-4):341-50. PubMed ID: 4323524
    [No Abstract] [Full Text] [Related]

  • 32. [The efficacy of foot and mouth disease vaccines after long- term storage].
    Wittmann G.
    Berl Munch Tierarztl Wochenschr; 1980 Jan 15; 93(2):33-4. PubMed ID: 6248022
    [No Abstract] [Full Text] [Related]

  • 33. Serological comparison of a type sat 2 foot-and-mouth disease virus isolate from Sudan with other type SAT 2 strains.
    Abu Elzein EM, Crowther JR.
    Bull Anim Health Prod Afr; 1979 Dec 15; 27(4):245-8. PubMed ID: 232850
    [No Abstract] [Full Text] [Related]

  • 34. Biological behaviour & antigenicity of mouse passaged & formol inactivated foot & mouth disease virus type Asia-1 in guineapigs.
    Saraswat KC, Sharma KN, Mehrotra PN.
    Indian J Exp Biol; 1980 Mar 15; 18(3):275-8. PubMed ID: 6248457
    [No Abstract] [Full Text] [Related]

  • 35. [Determination of effectiveness of FMD vaccine type Asia 1 in neutralization tests in cattle].
    Dimitriadis IA.
    Berl Munch Tierarztl Wochenschr; 1993 Apr 15; 106(4):124-7. PubMed ID: 8387775
    [Abstract] [Full Text] [Related]

  • 36. [Virological and serological studies of the internal eye in foot-and-mouth diseased cattle. II. Neutralization test and intraocular infection of guinea pigs].
    Kaaden OR.
    Arch Exp Veterinarmed; 1966 Jun 15; 20(3):595-7. PubMed ID: 4296903
    [No Abstract] [Full Text] [Related]

  • 37. Storage-related potency changes in monovalent type O1, A5 and C foot-and-mouth disease vaccine preparations.
    Sólyom F, Fazekas A, Czelleng F.
    Acta Vet Acad Sci Hung; 1981 Jun 15; 28(3):289-95. PubMed ID: 6266237
    [No Abstract] [Full Text] [Related]

  • 38. Immunoglobulin profiles in nasal and buccal secretions from normal crossbred calves after vaccination with inactivated virus and/or experimental exposure to foot-and-mouth disease virus type Asia I.
    Kapil S, Ahuja KL, Prasad S.
    Adv Exp Med Biol; 1987 Jun 15; 216B():1831-8. PubMed ID: 2827446
    [No Abstract] [Full Text] [Related]

  • 39. The biological relevance of virus neutralisation sites for virulence and vaccine protection in the guinea pig model of foot-and-mouth disease.
    Dunn CS, Samuel AR, Pullen LA, Anderson J.
    Virology; 1998 Jul 20; 247(1):51-61. PubMed ID: 9683571
    [Abstract] [Full Text] [Related]

  • 40. [Detection of antibody-forming cells by means of local hemolysis in gel (LHG) in mice and pigs after immunization with infectious or inactivated foot-and-mouth disease virus (author's transl)].
    Reda I, Wittmann G, Skoda R.
    Z Immunitatsforsch Exp Klin Immunol; 1974 Nov 20; 148(2):119-31. PubMed ID: 4143236
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.